JP2010539241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539241A5 JP2010539241A5 JP2010525943A JP2010525943A JP2010539241A5 JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5 JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- inhibitor
- clemizole
- compounds
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical group C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 claims 18
- 229950002020 clemizole Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 150000003839 salts Chemical group 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 241000710781 Flaviviridae Species 0.000 claims 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 125000002015 acyclic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 208000037404 Central European encephalitis Diseases 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241001466978 Kyasanur forest disease virus Species 0.000 claims 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims 1
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 241000710884 Powassan virus Species 0.000 claims 1
- 241000907329 Russian Spring-Summer encephalitis virus Species 0.000 claims 1
- 241000710888 St. Louis encephalitis virus Species 0.000 claims 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 C*1CCCC1 Chemical compound C*1CCCC1 0.000 description 5
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97330907P | 2007-09-18 | 2007-09-18 | |
| US60/973,309 | 2007-09-18 | ||
| US8875908P | 2008-08-14 | 2008-08-14 | |
| US61/088,759 | 2008-08-14 | ||
| US9253708P | 2008-08-28 | 2008-08-28 | |
| US61/092,537 | 2008-08-28 | ||
| PCT/US2008/076806 WO2009039248A2 (en) | 2007-09-18 | 2008-09-18 | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539241A JP2010539241A (ja) | 2010-12-16 |
| JP2010539241A5 true JP2010539241A5 (OSRAM) | 2012-11-08 |
| JP5715820B2 JP5715820B2 (ja) | 2015-05-13 |
Family
ID=40468758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525943A Expired - Fee Related JP5715820B2 (ja) | 2007-09-18 | 2008-09-18 | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8895598B2 (OSRAM) |
| EP (1) | EP2203168B1 (OSRAM) |
| JP (1) | JP5715820B2 (OSRAM) |
| CN (1) | CN101903026B (OSRAM) |
| AR (1) | AR066165A1 (OSRAM) |
| AU (1) | AU2008302295B2 (OSRAM) |
| TW (1) | TW200927102A (OSRAM) |
| WO (2) | WO2009039246A2 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009039246A2 (en) * | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
| US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| US9149463B2 (en) | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| JP2012520885A (ja) * | 2009-03-18 | 2012-09-10 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー | フラビウイルス科ウイルス感染症を治療する方法および組成物 |
| US20100284970A1 (en) * | 2009-04-09 | 2010-11-11 | Auspex Pharmaceuticals, Inc. | Benzimidazole modulators of h1 receptor and/or ns4b protein |
| WO2010132810A1 (en) * | 2009-05-15 | 2010-11-18 | Concert Pharmaceuticals, Inc. | Deuterium modified benzimidazoles |
| RU2407738C1 (ru) * | 2009-07-03 | 2010-12-27 | Общество с ограниченной ответственностью "Интеллектуальный Диалог" | Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US20120232062A1 (en) * | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| CN103619841B (zh) * | 2011-01-11 | 2017-03-29 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| US9388140B2 (en) | 2011-03-31 | 2016-07-12 | Bayer Intellectual Property Gmbh | Substituted benzimidazoles |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| SE1450019A1 (sv) | 2011-10-21 | 2014-01-10 | Abbvie Inc | Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| MY171759A (en) | 2011-12-06 | 2019-10-28 | Univ Leland Stanford Junior | Methods and compositions for treating viral diseases |
| EA028626B1 (ru) * | 2012-06-11 | 2017-12-29 | Юсб Байофарма Спрл | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α |
| CN103585616B (zh) * | 2013-08-14 | 2015-05-27 | 南京工业大学 | 二肽类似物的用途 |
| EP3035926B1 (en) | 2013-08-19 | 2020-07-29 | The Regents of The University of California | Compounds and methods for treating an epileptic disorder |
| EP3052219B1 (en) | 2013-10-01 | 2020-04-22 | The Broad Institute, Inc. | Sieve valves, microfluidic circuits, microfluidic devices, kits, and methods for isolating an analyte |
| LT3261640T (lt) | 2015-02-25 | 2022-07-11 | The Regents Of The University Of California | 5ht agonistai epilepsijos sutrikimų gydymui |
| US10688083B2 (en) * | 2015-06-30 | 2020-06-23 | Eiger Group International, Inc. | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
| SG11201808237UA (en) * | 2016-04-01 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole compound derivatives as dengue viral replication inhibitors |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| MX384261B (es) | 2016-04-11 | 2025-03-14 | Genfit | Metodos de tratamiento para enfermedades colestasicas y fibroticas. |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS |
| WO2018129702A1 (zh) * | 2017-01-13 | 2018-07-19 | 史仅 | 蚊虫叮咬瘙痒寨卡等病毒预防医疗器具 |
| CN108096562B (zh) * | 2017-12-25 | 2021-05-11 | 武汉百药联科科技有限公司 | 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途 |
| WO2019126860A1 (pt) * | 2017-12-29 | 2019-07-04 | Instituto Butantan | Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição |
| CN108660253B (zh) * | 2018-04-17 | 2022-05-31 | 广东省妇幼保健院（广东省妇产医院、广东省儿童医院） | 一种基于悬浮微珠阵列系统检测虫媒介病毒的探针、引物、检测试剂盒及检测方法 |
| CN109020895B (zh) * | 2018-08-07 | 2020-04-24 | 枣庄学院 | 一种金属催化的1-苄胺基取代苯并咪唑的合成方法 |
| SI3860998T1 (sl) | 2018-10-05 | 2024-06-28 | Annapurna Bio Inc. | Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja |
| US20200323830A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with etoricoxib |
| WO2021030268A2 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| WO2021180251A1 (zh) * | 2020-03-09 | 2021-09-16 | 北京强新生物科技有限公司 | 治疗冠状病毒感染的联用药物及治疗方法 |
| CN111393372B (zh) * | 2020-05-12 | 2022-08-26 | 中国药科大学 | 一种苯并咪唑衍生物及其制备方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| JP2025518536A (ja) * | 2022-05-20 | 2025-06-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 脂肪肝及びウイルス感染症を治療するための方法及び組成物 |
| CN119707828B (zh) * | 2024-12-18 | 2025-12-05 | 江苏天和制药股份有限公司 | 一种盐酸克立咪唑的合成方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689853A (en) * | 1954-09-21 | Certain i | ||
| US2684327A (en) * | 1951-11-02 | 1954-07-20 | United Chromium Inc | Bright nickel plating |
| GB1045534A (en) * | 1963-02-09 | 1966-10-12 | Schering Ag | New 1-benzyl-5,6-dialkoxy benzimidazoles and a process for their manufacture |
| DE1620450C3 (de) * | 1964-07-23 | 1976-01-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 1 - (2- Hydroxybenzyl) -2-piperazinomethylbenzimidazole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US3428634A (en) * | 1965-03-13 | 1969-02-18 | Acraf | 3-tertiary amino alkoxy-1-hydrocarbon indazoles |
| DE2436883C2 (de) * | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4269835A (en) * | 1979-12-13 | 1981-05-26 | Whittle Barry J | Nasal composition for relieving nasal distress |
| ZA953311B (en) | 1994-04-29 | 1996-10-24 | Lilly Co Eli | Non-peptidyl tachykinin receptor antagonists |
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| DE69814049T2 (de) * | 1997-02-25 | 2004-02-19 | The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| US6770666B2 (en) * | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6476062B2 (en) * | 2000-03-30 | 2002-11-05 | Schering Corporation | Chemokine receptor antagonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
| DE60204224T2 (de) * | 2001-03-22 | 2006-02-02 | Ucb S.A. | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen |
| AR035543A1 (es) * | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| WO2003060475A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| WO2004073614A2 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of immunoinflammatory disorders |
| PL1611088T3 (pl) * | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| CA2534649A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
| US7582428B2 (en) | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
| TW200522932A (en) * | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20070269420A1 (en) * | 2003-11-24 | 2007-11-22 | Chunduru Srinivas K | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases |
| JP2007523937A (ja) | 2004-02-27 | 2007-08-23 | エフ．ホフマン−ラ ロシュ アーゲー | インダゾール誘導体およびそれを含む医薬組成物 |
| GB0416728D0 (en) | 2004-07-27 | 2004-09-01 | 7Tm Pharma As | Medicinal use of receptor ligands |
| AU2005287407B2 (en) | 2004-07-27 | 2011-11-17 | Gilead Sciences, Inc. | Imidazo(4,5-d)pyrimidines, their uses and methods of preparation |
| WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| MX2007015577A (es) * | 2005-06-09 | 2008-02-25 | Biolipox Ab | Metodo y composiciones para el tratamiento de trastornos inflamatorios. |
| US7872037B2 (en) * | 2006-03-02 | 2011-01-18 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| MX2008011968A (es) | 2006-03-31 | 2008-10-01 | Astrazeneca Ab | Compuestos biciclicos de bencimidazol y su uso como potenciadores del receptor metabotropico de glutamato. |
| WO2008033466A2 (en) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| WO2009039246A2 (en) * | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
| US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
-
2008
- 2008-09-18 WO PCT/US2008/076804 patent/WO2009039246A2/en not_active Ceased
- 2008-09-18 AU AU2008302295A patent/AU2008302295B2/en not_active Ceased
- 2008-09-18 AR ARP080104066A patent/AR066165A1/es unknown
- 2008-09-18 EP EP08832123.7A patent/EP2203168B1/en not_active Not-in-force
- 2008-09-18 US US12/678,014 patent/US8895598B2/en not_active Expired - Fee Related
- 2008-09-18 US US12/677,989 patent/US9061010B2/en not_active Expired - Fee Related
- 2008-09-18 JP JP2010525943A patent/JP5715820B2/ja not_active Expired - Fee Related
- 2008-09-18 TW TW097135844A patent/TW200927102A/zh unknown
- 2008-09-18 WO PCT/US2008/076806 patent/WO2009039248A2/en not_active Ceased
- 2008-09-18 CN CN200880116387XA patent/CN101903026B/zh not_active Expired - Fee Related
-
2014
- 2014-09-23 US US14/493,529 patent/US20150044169A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539241A5 (OSRAM) | ||
| JP2011521903A5 (OSRAM) | ||
| JP2011518835A5 (OSRAM) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| RU2483073C2 (ru) | Фосфадиазиновые ингибиторы iv полимеразы hcv | |
| AR066165A1 (es) | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae | |
| JP2014514308A5 (OSRAM) | ||
| ES2671478T3 (es) | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales | |
| ES2680550T3 (es) | Combinaciones de inhibidores del virus de la hepatitis C | |
| RU2011133741A (ru) | Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae | |
| JP2012504126A5 (OSRAM) | ||
| JP2008518943A5 (OSRAM) | ||
| JP2016518359A5 (OSRAM) | ||
| JP2013521279A5 (OSRAM) | ||
| JP2013517286A5 (OSRAM) | ||
| JP2015525220A5 (OSRAM) | ||
| JP2012519691A5 (OSRAM) | ||
| JP2014503516A5 (OSRAM) | ||
| HRP20140219T1 (hr) | Analozi karba-nukleozida za antivirusno lijeäśenje | |
| JP2010532352A5 (OSRAM) | ||
| JP2012504632A5 (OSRAM) | ||
| JP2012513479A5 (OSRAM) | ||
| JP2011511841A5 (OSRAM) | ||
| JP2011528713A5 (OSRAM) | ||
| JP2005533824A5 (OSRAM) |